Delivery Order SPE2DB20D2014-SPE2DB25FC51C
- Not listed
- The Defense Logistics Agency awarded a $1,201.32 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pharmaceutical product, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,254.40 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as a...
- The Defense Logistics Agency awarded a $3,471.40 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for REPATHA 140 mg/ml SureClick auto-injectors, with final delivery scheduled for April 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with the DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,826.84 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical product will...
- The Defense Logistics Agency awarded a delivery order valued at $8,232.28 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 13, 2025. This competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $4,540.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 16, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of REPATHA 140 mg/ml SureClick auto-injector pharmaceutical product. This $3,920.72 firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 28, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,393.01 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 MG/ML SureClick auto-injectors. The contract, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed price delivery order with no set-aside designation. This award was made under a competitive procurement process, reflecting AmerisourceBergen's capability to meet federal pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a $41,759.43 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is the vendor's...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC51CDelivery Order
The Defense Logistics Agency has awarded a delivery order valued at $4,865.38 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.999 billion and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medications and medical devices to support military healthcare programs and other federal medical supply chain requirements. REPATHA is a cholesterol-lowering medication used in cardiovascular disease management, reflecting the company's role in providing specialty pharmaceuticals to Defense Health Agency and other federal healthcare systems. The non-set-aside status of this award underscores the company's competitive capability to fulfill federal medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 7/18/25 |